# Chinese expert consensus on the diagnosis and management of Epstein-Barr virus positive diffuse large B cell lymphoma（2025）

## TL;DR

This paper presents a Chinese expert consensus on diagnosing and managing a rare and aggressive type of lymphoma caused by the Epstein-Barr virus.

## Contribution

The paper introduces a unified expert consensus to improve diagnosis and treatment standards for EBV+ DLBCL in China.

## Key findings

- EBV+ DLBCL is a rare and aggressive lymphoma subtype with poor prognosis.
- There is a lack of standardized treatment for EBV+ DLBCL in China due to low incidence.
- The consensus aims to enhance clinical understanding and promote multicenter research.

## Abstract

EB病毒阳性弥漫大B细胞淋巴瘤（EBV+ DLBCL）是侵袭性弥漫大B细胞淋巴瘤的特殊亚型，预后不良。由于EBV+ DLBCL发病率低，我国临床医师对疾病的认识尚未统一，治疗缺乏规范性。为加强我国临床医师对EBV+ DLBCL的认识，提高诊断及治疗水平，推动开展多中心临床研究，中华医学会血液学分会淋巴细胞疾病学组、中国临床肿瘤学会（CSCO）淋巴瘤专家委员会组织相关专家，结合国内外最新研究进展，讨论并形成本共识。